


**Product Name** : BLZ945  
**Cat. No.** : PC-43194  
**CAS No.** : 953769-46-5  
**Molecular Formula** : C<sub>20</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub>S  
**Molecular Weight** : 398.4787  
**Target** : c-Fms (CSF1R)  
**Solubility** : DMSO: ≥ 30 mg/mL



## Biological Activity

Sotuletinib (BLZ945) is a potent, selective, brain-penetrant **CSF-1R** inhibitor with biochemical IC<sub>50</sub> of 1 nM, displays >3,200-fold selectivity over other kinases (c-Kit, PDGFR-β, Flt3, Abl, etc.).

Sotuletinib (BLZ945) inhibits CSF-1-dependent proliferation in bone marrow-derived macrophages (BMDMs) with EC<sub>50</sub> of 67 nM, and decreases CSF-1R phosphorylation.

Sotuletinib (BLZ945) blocks glioma progression and significantly improves survival, efficiently limits tumor progression combining with PD-1/PD-L1 blocking antibodies in neuroblastoma.

## References

Pyonteck SM, et al. *Nat Med*. 2013 Oct;19(10):1264-72.

Pass HI, et al. *Oncotarget*. 2016 Aug 30;7(35):56408-56421.

Mao Y, et al. *Clin Cancer Res*. 2016 Aug 1;22(15):3849-59.

Quail DF, et al. *Science*. 2016 May 20;352(6288):aad3018.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com